A Comparative Study of Topical Mitomycin C, Cyclosporine, and Bevacizumab after Primary Pterygium Surgery
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To compare the recurrence rates and complications associated with instillation of topical mitomycin C, cyclosporine, and bevacizumab after primary pterygium surgery. Methods: Between July 2013 and June 2014, we performed surgery using the bare sclera method on 132 eyes (132 patients) with primary pterygium. We randomly selected 33 eyes (33 patients) and treated them with artificial tears four times a day for three months, 29 eyes (29 patients) were treated with topical 0.02% mitomycin C four times a day for five days, 34 eyes (34 patients) were treated with topical 0.05% cyclosporine four times a day for three months, and 36 eyes (36 patients) were treated with topical 2.5% bevacizumab four times a day for three months after surgery. We prospectively determined the recurrence rates of pterygium and complications at the six-month follow-up examination. Results: At six months after surgery, the recurrence rates in each group were as follows: 45.5% (15 eyes) in the control group, 10.3% (three eyes) in the mitomycin C group, 20.6% (seven eyes) in the cyclosporine group, and 41.7% (15 eyes) in the bevacizumab group (p = 0.004). No serious complications, except subconjunctival hemorrhages, were observed in any group. Conclusions: Groups receiving topical 0.02% mitomycin C and 0.05% cyclosporine after surgery showed lower recurrence rates than the control group; however, no difference in recurrence rate was observed between the control group and the group receiving topical 2.5% bevacizumab after surgery.
Abstract
Purpose: To compare the recurrence rates and complications associated with instillation of topical mitomycin C, cyclosporine, and bevacizumab after primary pterygium surgery. Methods: Between July 2013 and June 2014, we performed surgery using the bare sclera method on 132 eyes (132 patients) with primary pterygium. We randomly selected 33 eyes (33 patients) and treated them with artificial tears four times a day for three months, 29 eyes (29 patients) were treated with topical 0.02% mitomycin C four times a day for five days, 34 eyes (34 patients) were treated with topical 0.05% cyclosporine four times a day for three months, and 36 eyes (36 patients) were treated with topical 2.5% bevacizumab four times a day for three months after surgery. We prospectively determined the recurrence rates of pterygium and complications at the six-month follow-up examination. Results: At six months after surgery, the recurrence rates in each group were as follows: 45.5% (15 eyes) in the control group, 10.3% (three eyes) in the mitomycin C group, 20.6% (seven eyes) in the cyclosporine group, and 41.7% (15 eyes) in the bevacizumab group (p = 0.004). No serious complications, except subconjunctival hemorrhages, were observed in any group. Conclusions: Groups receiving topical 0.02% mitomycin C and 0.05% cyclosporine after surgery showed lower recurrence rates than the control group; however, no difference in recurrence rate was observed between the control group and the group receiving topical 2.5% bevacizumab after surgery.
참고문헌 (24)
- Todani A, "Pterygium: current concepts in pathogenesis and treatment", Int Ophthalmol Clin, 49, pp.21~30 (2009)
- Cho BJ, "Mitomycin C single soaking during surgery for primary pterygium", J Korean Ophthalmol Soc, 37, pp.927~933 (1996)
- Turan-Vural E, "The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery", Clin Ophthalmol, 5, pp.881~885 (2011)
- Bahrassa F, "Postoperative beta radiation treatment of pterygium", Int J Radiat Oncol Biol Phys, 9, pp.679~684 (1983)
- Na KS, "A clinical observation on the argon laser effect of the pterygium", J Korean Ophthalmol Soc, 37, pp.1120~1125 (1996)
- Shenasi A, "Subconjunctival bevacizumab immediately after excision of primary pterygium:the first clinical trial", Cornea, 30, pp.1219~1222 (2011)
- Kawase K, "Mitomycin concentration in rabbit and human ocular tissues after topical administration", Ophthalmology, 99, pp.203~207 (1992)
- Strong B, "Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca", Cornea, 24, pp.80~85 (2005)
- Ozgurhan EB, "Topical application of bevacizumab as an adjunct to recurrent pterygium surgery", Cornea, 32, pp.835~838 (2013)
- Yamanouchi U, "Scleral changes induced by instillation of mitomycin C", Acta Med Nagasaki, 28, pp.99~110 (1983)
- Rubinfeld RS, "Serious complications of topical mitomycin-C after pterygium surgery", Ophthalmology, 99, pp.1647~1654 (1992)
- Ibanez M, "Topical cyclosporin A and mitomycin C injection as adjunctive therapy for prevention of primary pterygium recurrence", Ophthalmic Surg Lasers Imaging, 40, pp.239~244 (2009)
- Stevenson W, "Corneal neovascularization and the utility of topical VEGF inhibition:ranibizumab (Lucentis) vs bevacizumab (Avastin)", Ocul Surf, 10, pp.67~83 (2012)
- Chen JJ, "Potential penetration of topical ranibizumab (Lucentis) in the rabbit eye", Eye (Lond), 25, pp.1504~1511 (2011)
- Tan DT, "Effect of pterygium morphology on pterygium recurrence in a controlled trial comparing conjunctival autografting with bare sclera excision", Arch Ophthalmol, 115, pp.1235~1240 (1997)
- Prabhasawat P, "Comparison of conjunctival autografts, amniotic membrane grafts, and primary closure for pterygium excision", Ophthalmology, 104, pp.974~985 (1997)
- 송영수, "익상편 발생기전에서 말초혈액의 내피전구세포 및 혈관신생인자의 관여", 대한안과학회지, 47(9), pp.1472~1480 (2006), 대한안과학회
- Yalcin Tok O, "Topical cyclosporine A in the prevention of pterygium recurrence", Ophthalmologica, 222, pp.391~396 (2008)
- Lazic R, "Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration", Graefes Arch Clin Exp Ophthalmol, 245, pp.68~73 (2007)
- Jorge R, "Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study)", Retina, 26, pp.1006~1013 (2006)
- Motarjemizadeh Q, "A comparative study of different concentrations of topical bevacizumab on the recurrence rate of excised primary pterygium: a short-term follow-up study", Int Ophthalmol (2015)[DOI]
- 서재신, "원발성군날개 수술 후 베바시주맙 결막하 주사의 효과", 대한안과학회지, 54(1), pp.53~59 (2013), 대한안과학회
- Krohne TU, "Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans", Am J Ophthalmol, 146, pp.508~512 (2008)
- 이종수, "익상편조직의 섬유모세포에 미치는 사이클로스포린의 영향", 대한안과학회지, 53(3), pp.466~472 (2012), 대한안과학회